Treats hypertension. ANDA 76719, held by Macleods Pharmaceuticals. Amlodipine Besylate.
As of Nov 21, 2026, ANDA 76719 (Amlodipine Besylate), held by Macleods Pharmaceuticals, was first approved by FDA on May 23, 2007, with 5 approved supplements and 0 published complete response letters.
Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease Chronic Stable Angina Vasospastic Angina (Prinzmetal’s or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40% 1.1 Hypertension
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 23, 2007 | Original application | Approved | None posted |
| Amlodipine BesylateEQ 2.5MG BASE · tablet;oral | Amlodipine Besylate | Rx |
| Amlodipine BesylateEQ 5MG BASE · tablet;oral | Amlodipine Besylate | Rx |
| Amlodipine BesylateEQ 10MG BASE · tablet;oral | Amlodipine Besylate | Rx |
| Apr 2, 2018 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 25, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 26, 2013 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 26, 2013 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 22, 2011 | Supplement 6Labeling | Approved | None posted |
| May 23, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters